Total revenues
 |
$6.3 billion
 |
$5.7 billion
 |
11%
 |

Operating earnings, excluding development**
|
$437.3 million |
$352.3 million |
24% |
|
Net income
|
$476.4 million |
$372.8 million |
28% |
|
Per share results:
|
|
|
|
|
Operating earnings**
|
$0.84 |
$0.61 |
38% |
|
Favorable development of prior-period health care cost estimates
|
(0.06) |
(0.03) |
|
|
Operating earnings, excluding development**
|
$0.78 |
$0.58 |
34% |
|
Net income
|
$0.85 |
$0.62 |
37% |
|
Weighted average common shares (diluted)
|
558.1 million |
602.6 million |
|
* Restated for FAS123R and stock split. Refer to footnote 2 at the end of this press release.
** For a full description of operating earnings and per-share operating earnings, refer to footnote 1 at the end of this press release.
|